Navigation Links
Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update
Date:12/16/2008

g L-DOS47 and Topical Interferon Alpha-2b, will be successfully developed and commercialized as drugs or at all; uncertainty whether clinical trials will proceed as planned or at all, and the risk that clinical trial results may be negative; product liability, insurance and intellectual property risks; research and development risks; the need for further regulatory approvals, which may not be obtained; the Company's dependence on its contract service providers, licensors, optionees and other collaborators for performance; upscaling and manufacturing risks; partnership / strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; changes in business strategy or plans; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with securities regulatory authorities, including its latest Annual Information Form at www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CSL Behrings Helixate(R) FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance
2. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
3. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
4. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
5. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
6. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
7. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
8. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
9. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
10. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
11. Immunosyn Announces Proposed Agreements for Distribution of the Biopharmaceutical SF-1019 in Utah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... Invitation to Cover: , Most ... a large gap between the unmet health priorities in the region and the ... reduce unnecessary or ineffective treatments or procedures. , This milestone conference, sponsored by ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... fat-reduction procedures each year for aesthetic reasons, which is why liposuction regularly ranks ... a particular demographic, however, fat reduction has become more than a way to ...
(Date:7/6/2015)... London, UK (PRWEB) , ... July 06, 2015 , ... ... 5.58 billion in 2014. It is expected to grow at a CAGR of over ... by 2021. , The growth is likely to be mainly spurred by an anticipated ...
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. Jason ... department of Family Practice. , “This award is a real honour,” says Dr Hitkari. ... changing so rapidly and we are also developing new models of patient-centred care that ...
(Date:7/6/2015)... ... July 06, 2015 , ... Understanding the new ... ADVOCATE is leading the transition. ADVOCATE, the only 100% radiology, revenue cycle management ... Tips for ICD-10. The ten tips are timely and relevant guidelines to help ...
Breaking Medicine News(10 mins):Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:APAC Rheumatoid Arthritis Therapeutics Market to Reach Value of USD 6.9 Billion by 2021, Says GBI Research in Its New Report Now Available at MarketPublishers.com 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:ADVOCATE Takes the Lead to Ensure ICD-10 Success: “Top 10 Tips for ICD-10” 2
... $0.18 Earnings per Share, BILLERICA, Mass., Oct. 23 ... provider of precision technology and,semiconductor systems, today announced financial ... Third quarter revenue was $84.0 million, compared to $73.1 ... for the third quarter of 2006.,Excluding restructuring charges, operating ...
... Aflac Incorporated,today reported its third quarter results. Reflecting ... 5.1% to $3.9,billion during the third quarter of 2007, ... Net earnings were $420 million, or $.85 per diluted,share, ... year ago. Net,earnings included realized investment gains of $1 ...
... With the discovery of suitable molecular targets cellular ... cancer cells comes the perplexing dilemma of where ... and disable those targets. While the possibilities for drug ... and repositories are often problematic or ill-suited for the ...
... clay in unvented kilns could be a significant source ... periods, a new study suggests. , The results came ... the University of Michigan Dioxin Exposure Study, which measured ... River flood plain between Midland and Saginaw. , The ...
... SAN FRANCISCO -- Mayo Clinic today reported promising interim ... combination therapy for patients with recurrent ovarian cancer that ... participants achieved either complete or partial tumor regression from ... Findings from this Phase 2 Consortium (P2C) clinical trial ...
... Disorder Without Disturbing Patients, CHICAGO, Oct. 23 ... measuring airflow by nasal pressure, temperature, and/or carbon,dioxide, ... method is,uncomfortable to some and can potentially disturb ... 73rd annual international scientific assembly,of the American College ...
Cached Medicine News:Health News:GSI Group Reports Third Quarter Results 2Health News:GSI Group Reports Third Quarter Results 3Health News:GSI Group Reports Third Quarter Results 4Health News:GSI Group Reports Third Quarter Results 5Health News:GSI Group Reports Third Quarter Results 6Health News:GSI Group Reports Third Quarter Results 7Health News:GSI Group Reports Third Quarter Results 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 2Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 3Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 4Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 5Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 6Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 7Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 8Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 9Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 10Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 11Health News:Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend 12Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 2Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 3Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 4Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 5Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 6Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 7Health News:Advances in drug screening: building a better haystack for the needles of tomorrow 8Health News:Firing clay in unvented kilns may be a source of exposure to dioxins 2Health News:Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 2Health News:Infrared Imaging for Sleep Apnea Diagnosis Shows Promise 3
(Date:7/6/2015)... July 6, 2015 Flower Orthopedics, the ... the FlowerCube™, announced today that it has received ... for significant expansion of the innovative FlowerCube™ concept ... approval encompasses Flower Orthopedics, entire product line, which ... and lower extremities. Consisting of more than 400 ...
(Date:7/6/2015)... -- Mauna Kea Technologies (Euronext: MKEA, ... endomicroscopy platform, announced today it has obtained approval ... Health, Labor and Welfare (MHLW) for its unique ... miniprobe.   Used during endoscopy procedures, ... of a fiber-optic microscope that is small enough ...
(Date:7/6/2015)... July 6, 2015 RoundTable Healthcare Partners ... on the healthcare industry, announced today that it ... or the "Company"). Founded in 1969 in ... primarily a manufacturer of paper-based barrier products. Through ... TIDI has expanded its product offering to include ...
Breaking Medicine Technology:Flower Orthopedics cleared to enter the European Union 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3RoundTable Healthcare Partners Acquires TIDI Products 2RoundTable Healthcare Partners Acquires TIDI Products 3
... , - Used during coronary angioplasty plus stenting, ... a new reversible blood thinner did not have a ... of all-cause mortality, heart attack and need for new ... investigational drug significantly lessened the risk for two pre-specified ...
... Md., Nov. 13 The U.S. Food and Drug ... non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). ... to clot. , (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ... year by about 3 million U.S. women of reproductive ...
Cached Medicine Technology:American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 2American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis 3FDA Approves Lysteda to Treat Heavy Menstrual Bleeding 2
This table has adjustable height, square post and adjustable leg. Includes clamps, and standard 1" (2.5 cm) pad....
... versatile model angulates for vascular procedures. ... height of the support leg, which ... or double tee foot. Add up ... and stability. A convenient bracket is ...
The Biomet® CHS is indicated for intertrochanteric, subtrochanteric and basilar neck fractures of the proximal femur....
... trauma procedures. Part of the osi ... table top provides a complete, powered, ... and provides for skin or skeletal ... pinnings; femur, supine or lateral im ...
Medicine Products: